Ex­clu­sive: ADC start­up Myth­ic re­cruits Jazz ex­ec to lead com­pa­ny; Dyne’s CEO shuf­fle

Myth­ic Ther­a­peu­tics has gone more than a year and a half with­out a CEO.

That’s chang­ing on April 1, as George Eli­ades will join the Waltham, MA-based an­ti­body-drug con­ju­gate biotech. Eli­ades is com­ing from Jazz Phar­ma­ceu­ti­cals, where he’s served as se­nior vice pres­i­dent of cor­po­rate de­vel­op­ment and chief trans­for­ma­tion of­fi­cer for the past three and a half years.

In the in­ter­im, Myth­ic’s CEO du­ties were shared among chief sci­en­tist Bri­an Fiske, COO San­dra Poole and chief de­vel­op­ment of­fi­cer Gilles Gal­lant, ac­cord­ing to a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER